For UK HealthTech & MedTech companies
You don't know the size of your market, which means you can't prioritise, can't fundraise, and can't focus
Without a credible TAM, your commercial strategy is built on guesswork. You can't prioritise segments, make a compelling investment case, or allocate sales resource efficiently. The gap between your current revenue and your reachable market is the number that should drive every GTM decision.
Cost of Inaction
Enter your target accounts, contracts live today, average contract value, and achievable conversion rate. The calculator shows the revenue gap between today and your reachable market.
How it breaks down
- Current contracted revenue£270,000
- Revenue at target penetration£324,000
Two minutes, no typing, and I read every one myself.
From Paul
Tell me where that £54,000 is coming from, and I'll come back with the three things to fix first.
A few quick questions, about two minutes, and no typing. I read every one myself and reply with the three things costing you most and where I'd start. If it's useful, we talk. If not, you've still got a clear picture.
No obligation, no sales call unless you ask for one, and nothing automated lands in your inbox.
Paul, Solvable
- Investor decks cite a large market figure with no bottom-up support
- Sales team pursues accounts of all sizes without clear prioritisation
- No consensus internally on how big the opportunity actually is
- investor conversations stall on market size credibility
- sales team has no clear prioritisation framework
- Strategic: resource allocation is based on intuition not market structure
Frequently asked questions
Why does this problem persist?
TAM is usually estimated top-down from a market report rather than built bottom-up from real buyer data. The result is a number that sounds big but doesn't hold up in a due diligence conversation, because it hasn't been constructed from actual account counts, budget cycles, and addressable segments.
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.